APF530 (Granisetron Injection Extended-Release) in a Three-Drug Regimen for Delayed CINV in Highly Emetogenic Chemotherapy
Nurses urge “zero tolerance” for CINV
Types of CINV and risk factors
Reducing CINV with ginger.
Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV)
Personalisierte Antiemese reduziert CINV
Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy
Bringing it all together in the treatment of CINV: application of current knowledge into routine clinical practice
Nausea/Vomiting: Chemotherapy-Induced (CINV)
Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population
